Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Anlotinib + Epirubicin in T4 Sinonasal Adenoid Cystic Carcinoma
NCT07616141Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, epirubicin in adenoid cystic carcinoma (ACC), sponsored by Eye and ENT Hospital of Fudan University. Started Jun 2026; status: recruiting.
02
Drugs
anlotinibepirubicin
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT07616141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616141.